➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
Express Scripts
Dow
McKesson
Baxter

Last Updated: July 12, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Arbaclofen


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Arbaclofen?

Arbaclofen is an investigational drug.

There have been 28 clinical trials for Arbaclofen. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2011.

The most common disease conditions in clinical trials are Autism Spectrum Disorder, Child Development Disorders, Pervasive, and Autistic Disorder. The leading clinical trial sponsors are Seaside Therapeutics, Inc., Indivior Inc., and Osmotica Pharmaceutical US LLC.

There are nineteen US patents protecting this investigational drug and one hundred and forty-seven international patents.

Recent Clinical Trials for Arbaclofen
TitleSponsorPhase
Safety, Tolerability, and Efficacy of Arbaclofen in 16p11.2 DeletionClinical Research Associates, LLCPhase 2
Arbaclofen in Children and Adolescents With ASDHospital General Universitario Gregorio MarañonPhase 2
Arbaclofen in Children and Adolescents With ASDInge WinterPhase 2

See all Arbaclofen clinical trials

Clinical Trial Summary for Arbaclofen

Top disease conditions for Arbaclofen
Top clinical trial sponsors for Arbaclofen

See all Arbaclofen clinical trials

US Patents for Arbaclofen

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Arbaclofen   Start Trial Acyloxyalkyl carbamate prodrugs, methods of synthesis and use ARBOR PHARMACEUTICALS, LLC (Atlanta, GA)   Start Trial
Arbaclofen   Start Trial Acyloxyalkyl carbamate prodrugs, methods of synthesis and use XenoPort, Inc. (Santa Clara, CA)   Start Trial
Arbaclofen   Start Trial Acyloxyalkyl carbamate prodrugs, methods of synthesis and use Xenoport, Inc. (Santa Clara, CA)   Start Trial
Arbaclofen   Start Trial Acyloxyalkyl carbamate prodrugs, methods of synthesis and use XenoPort, Inc. (Santa Clara, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Arbaclofen

Drugname Country Document Number Estimated Expiration Related US Patent
Arbaclofen Austria 546427 2023-08-20   Start Trial
Arbaclofen Australia 2004267100 2023-08-20   Start Trial
Arbaclofen Australia 2010219384 2023-08-20   Start Trial
Arbaclofen Brazil PI0413756 2023-08-20   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Merck
McKinsey
Baxter
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.